Codetta Bio Announces Commercial Availability of Concerto™ System and New Customizable Cytokine and Neuroscience Panels at AGBT 2026
· Financial Post
ORLANDO, Fla., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Codetta Bio™, a leader in multi-omic solutions that combine ultrasensitive protein quantification with simultaneous RNA and DNA analysis, today announced major product and commercialization milestones at the AGBT General Meeting. The company has transitioned its Concerto™ system to commercial production and has begun installing systems at customer sites. Codetta Bio also unveiled its near-term product roadmap, including the upcoming launch of new customizable panels for multi-omic studies of immunology and neuroscience. Read More
Visit librea.one for more information.